Protagenic Therapeutics (PTIX) Stock Rises Following Advancements in Clinical Trials

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Aug 21 2025

0mins

Should l Buy ?

Source: Benzinga

Stock Performance: Shares of Protagenic Therapeutics Inc (PTIX) surged over 100% after the announcement of a key clinical milestone in their Phase 1 trial for PT00114, a hormone therapy targeting stress and mood disorders.
Clinical Trial Update: The company successfully administered the first dose to all subjects in the multiple-dose portion of the trial and expects to complete dosing by the end of August, with topline safety data anticipated by the end of September.
Therapeutic Approach: PT00114 is based on Teneurin C-terminus Associated Peptide, a naturally occurring brain hormone aimed at regulating stress and emotional balance, potentially offering a treatment with fewer side effects.
Current Stock Price: As of Thursday afternoon, PTIX shares were trading at $4.02, reflecting a 76% increase, with a notable 52-week high of $15.54 and a low of $2.25.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free